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ABSTRACT 
Mevalonate kinase (MvK) is a metabolic enzyme involved in cholesterol biosynthesis. It 
also serves as an RNA binding protein in luteinizing hormone receptor (LHR) down-
regulation that occurs after the LH surge. Because of this property, the enzyme is referred 
to as LHR mRNA binding protein (LRBP). The mechanism of the LHR down-regulation 
pathway and the role of LRBP have been extensively studied by the Menon laboratory. 
What has yet to be investigated is what occurs in the ovarian cycle when LRBP is 
completely absent. In this paper, a knockout mouse model is outlined that selectively 
knocks out the gene coding for LRBP in the ovaries. In order for the Transgenic Animal 
Model Core (TAMC) to carry out the creation of the LRBP knockout mouse model, it is 
imperative to develop a Southern blot assay that will be able to detect the presence of the 
LRBP knockout targeting vector in embryonic stem (ES) cells. To conduct the Southern 
blot assay, radioactively labeled probes must be prepared that will bind the targeting 
vector, revealing its presence in the ES cells. In addition to discussing the strategy used in 
the design of the targeting vector and the creation of the knockout mice, this paper also 
explains the steps involved in the refinement and amplification of the probes for Southern 
blot analysis. 
 
INTRODUCTION 
The ovarian cycle in most mammals involves follicle recruitment, maturation, 
ovulation, luteinization, and luteolysis [1]. These processes are regulated by two anterior 
pituitary hormones, luteinizing hormone (LH) and follicle-stimulating hormone (FSH). 
FSH regulates follicle recruitment and maturation whereas LH controls pre-ovulatory 
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steroidogenesis, ovulation, and corpus luteum function. FSH has an important role in 
follicle development and estrogen production by the ovary.  During follicle maturation, 
estradiol, produced by the pre-ovulatory follicles in response to FSH, plays a synergistic 
role with FSH in promoting the formation of Graafian follicles.  The expression of LH 
receptors increase in response to FSH action, and the LH receptors are responsible for 
responding to the pre-ovulatory LH surge that results in the release of the ovum for 
fertilization [2]. LH action is mediated by a membrane receptor family of G-protein-
coupled receptors (GPCRs). The expression of LH receptors shows dynamic changes 
during the ovarian cycle. For example, its expression increases during follicle maturation 
in response to FSH and undergoes down-regulation in response to the pre-ovulatory LH 
surge in order to keep the ovary in a transient quiescent state during the differentiation of 
granulosa cells to luteal cells. The LH receptor expression then increases to support 
progesterone synthesis by the corpus luteum. In the absence of fertilization, LH receptor 
expression declines coincident with the regression of the corpus luteum leading to the 
onset of the next cycle.  
Menon Lab has shown that the pre-ovulatory LH surge triggers the down-regulation 
of LH receptor expression through targeted degradation of LH receptor mRNA rather 
than the result of decreased transcription [3]. Both in rat and human ovaries, an LH 
receptor mRNA binding protein (LRBP) has been discovered, and this protein mediates 
LH receptor mRNA degradation through a post-transcriptional mechanism [4]. Menon 
lab also showed that LRBP selectively binds to the coding region of LH receptor mRNA 
and acts as a trans factor to target the mRNA for degradation. Furthermore, by altering 
the cellular levels of LRBP, ovarian LH receptor mRNA expression is regulated by 
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controlling its degradation [4,5]. In addition, the identity of LRBP was established as 
being mevalonate kinase (MvK)[4]. MvK is a cholesterol biosynthetic enzyme, and the 
identification of MvK as LRBP has suggested a link between LH receptor mRNA 
expression and sterol metabolism in ovarian tissue [4].  
Since the discovery of LRBP and its identity, our lab has focused on identifying the 
signaling pathways involved in LH receptor down-regulation. Similar to other GPCRs, an 
increase in cAMP levels results from LH or hCG binding to the LH receptor [5]. The 
increased concentration of cAMP in ovarian cells then leads to the activation of cAMP-
dependent protein kinase levels [5]. Increase in intracellular cyclic AMP levels were 
shown to decrease the expression of LH receptor mRNA while simultaneously increasing 
LRBP binding activity [6]. In addition, the well-known enzymes protein kinase A (PKA) 
and extracellular signal-regulating kinases 1 and 2 (ERK1/2) were found to have a vital 
role in the signaling pathways that leads to LRBP binding and subsequent LH receptor 
down-regulation [5]. PKA mediates LH receptor mRNA degradation through the 
activation of ERK1/2 signaling that leads to an increase in the levels of LRBP mRNA 
and LRBP protein [5]. ERKs, when activated, are known to phosphorylate many targets, 
which leads to the regulation of cell processes such as transcription, translation, and 
apoptosis [5]. Menon lab studied ERK activity in response to hCG stimulation and found 
that after treatment with hCG, ERK translocates to the nucleus and initiates events that 
result in the increased expression of LRBP [5]. This shows that it is likely that LRBP 
levels are regulated by transcriptional activation [5].  
The most recent studies being conducted in Menon laboratory investigate the roles of 
microRNA miR-122 and sterol regulatory element-binding proteins (SREBPs) in LRBP 
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expression.  Recently, microRNAs have been found to be increasingly important in gene 
expression and regulation [7]. They commonly perform their function by binding to the 
3’-untranslated region of protein-coding mRNA transcripts that either block translation or 
target the mRNA for degradation [7]. Our lab hypothesized that miR-122 could regulate 
LRBP expression based on previous studies which showed that the inhibition of miR-122 
in mouse liver also inhibits the expression of MvK [8]. Since MvK also functions as 
LRBP, Menon lab tested whether LRBP expression was affected by the presence of miR-
122 in rat ovaries [7].  Using in situ hybridization, we analyzed the localization of miR-
122 in rat ovaries and examined the changes in miR-122 expression during hCG-induced 
LH receptor down-regulation [7].  
 Using real-time PCR to observe the changing levels of miR-122 during hCG-
induced LH receptor down-regulation, it was found that there was a substantial increase 
of miR-122 expression 30 minutes after the rats were treated with hCG, and this increase 
peaked around 1-2 hours [7]. The presence of miR-122 was confirmed by fluorescent in 
situ hybridization (FISH) of the rat ovary [7]. In additional experiments, the increase in 
miR-122 expression was found to be followed by an increase in LRBP mRNA, which, in 
turn, was followed by an increase in LRBP protein levels [7]. This correlation implies a 
role of miR-122 in the regulation of LRBP in LH receptor mRNA down-regulation [7]. 
Furthermore, when PKA and ERK1/2 (which were shown in previous experiments to be 
included in the signaling cascade that leads to LH receptor down-regulation [5]), were 
suppressed, the expression of miR-122 was blocked, and hCG-mediated LH receptor 
mRNA down-regulation was abrogated [7]. This indicates that the cAMP/PKA and 
ERK1/2 pathways mediate miR-122, which, in turn, plays an integral role in LH receptor 
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mRNA down-regulation [7]. The final aspect of this pathway that was tested in the most 
recent study was the time course of SREBP activation in relation to miR-122-mediated 
LRBP induction [7]. In the time scale of LH receptor down-regulation, the activation of 
SREBP-2 and SREBP-1a occurred 1-4 hours after hCG treatment, which occurs between 
the peaks of miR-122 expression and LRBP expression [7]. Menon Lab also suppressed 
the effect of miR-122 on LH receptor down-regulation by injecting a locked nucleic acid 
(LNA) conjugated miR-122 antagomir directly into the bursa of the rat ovary [7]. This 
experiment, in its entirety, showed an important role for miR-122 on the LH receptor 
mRNA degradation pathway [7]. 
 While many of the relationships between LRBP and the major players discovered 
to be involved in LHR mRNA down-regulation have been investigated quite extensively 
as described above, our lab would now propose to investigate the physiological 
significance of LHR mRNA down-regulation in otherwise normal physiologic conditions. 
As indicated earlier, down-regulation of LHR mRNA in response to the pre-ovulatory LH 
surge to allow differentiation of granulosa cells to luteal cells and to suppress premature 
onset of vascular endothelial growth factor (VEGF) production to pressure normal 
ovarian function. However, availability of a model where LHR down-regulation is 
eliminated would reveal even potentially more interesting roles of LHR down-regulation 
in reproductive physiology. In order to conduct these experiments, we must engineer a 
genetically mutated “knockout mouse” that deletes the LRBP gene. Removing the gene 
that codes for LRBP, Mevk1, will allow our lab to study the impact of regulation of 
ovarian function by LHR, in the absence of LRBP. Additionally, the examination of 
LHR, LHR mRNA, miR-122, SREBP 1/2, and ERK 1/2 levels in the granulosa cells of 
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these mice will further elucidate, not only the role of LRBP in post-LH surge LHR down-
regulation, but the physiological importance of LHR down-regulation in general. There is 
a problem, however, with the universal knockout of Mevk1 that requires additional 
selection and cell differentiation. In addition its role as LRBP, it is well known that MvK 
catalyzes the phosphoryltransfer from a molecule of ATP to (R)-mevalonate to produce 
(R)-5-phosphomevalonate and ADP [9]. This reaction is a crucial step in isoprenoid and 
sterol biosynthesis pathways, and the systematic absence of expression of the enzyme is 
lethal [9]. Therefore, the design of a Mevk1 knockout mouse must include the excision 
Mevk1 exclusively in the ovaries.  
 This thesis discusses the long-range plans to genetically engineer a knockout 
mouse model (MvK cKO) that will selectively eliminate expression of mevalonate kinase 
(LRBP) in the ovaries of the mice. In this paper, multiple strategies are described, which 
are used to properly insert the knockout targeting vector, to excise it in the appropriate 
cell type, and to select for the mice with the desired knocked-out genotype. The knockout 
and selection tools that are discussed in this paper are the Cre-loxP approach using a 
Cyp19 primer, the PGK-Neo cassette used for embryotic stem cell selection, and the 
FLP-FRT knockout approach.  
Our lab is fortunate enough to have a central Transgenic Animal Model Core 
(TAMC) facility of the medical center for the creation of these mice [10]. Although the 
core facility will carry out most of the important steps, such as the microinjection of the 
targeting vector into embryonic stem (ES) cells for homologous recombination, the 
responsibility for screening the ES cells for the production of recombined LRBP is the 
responsibility of our laboratory [11]. TAMC’s protocol necessitates the completion of 
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certain tasks that ensures that our lab is capable of performing a Southern blot assay that 
detects the presence of the desired targeting vector [11]. To complete this requirement, 
we constructed two probes that bind complimentarily with sequences flanking our 
targeting vector that, when used in a Southern blot assay, would identify the presence of 
the targeting vector and confirm the success of proper homologous recombination in the 
ES cells. In addition to discussing the design behind our MvK cKO targeting vector, this 
paper will also demonstrate the process performed and results obtained from the 
amplification of these probes. My specific task in this process was to design primers for 
the probes and amplify them sufficiently for use in the crucial Southern blot verification 
assay. I accomplished this by first amplifying the probes from bacterial artificial 
chromosomes (BACs) using PCR and then through molecular cloning.  
 
MATERIALS AND METHODS 
Materials 
Dr. Michael Zeidler (Transgenic core, The University of Michigan) engineered the BAC 
containing the targeting vector. In the first intron of Mevk1, a loxP site was introduced, 
and in the third intron, another loxP site and an FRT-flanked PGK-Neo cassette were 
inserted. The 3’ and 5’ custom primers, and the competent DH5α cells were purchased 
from Thermo Fisher Scientific (Waltham, MA). The pBluescript II KS(-) plasmid was 
acquired from Agilent Technologies (Santa Clara, CA). The HindIII restriction enzyme, 
XhoI restriction enzyme, and T4 DNA Ligase were purchased from New England 
BioLabs (Ipswitch, MA). The Zymo Research Quick-gDNA Miniprep was acquired from 
Zymo Research (Irvine, CA). The QIAquick Nucleotide Removal Kit, QIAprep Spin 
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Miniprep Kit, and the QIAGEN Plasmid Maxi Kit were purchased from QIAGEN 
(Venlo, Netherlands). 
 
PCR Amplification 
3’-sense and 5’-sense primers were designed with XhoI restriction sites on the 5’ ends, 
and 3’-antisense and 5’-antisense primers were designed with HindIII restriction sites on 
the 5’ ends. The primers with 5’ restriction sites were used in the amplification of the 
probes using PCR and in the introduction of the XhoI and HindIII restriction sites 
flanking the probes. PCR mixture contained (one for each probe) 45 μL PCR Platinum 
Supermix, 2 μL DNA (BAC), 2 μL DepC H2O, 0.5 μL 3’/5’-sense primer (40 pmol/ μL), 
and 0.5 μL 3’/5’-antisense primer (40 pmol/ μL). The PCR cycle started with 
denaturation at 94 °C for 2 minutes and then repeated the following cycle 35 times: 94 °C 
for 30 seconds, 65 °C for 30 seconds, 72 °C for 18 seconds. This was followed by 10 
minutes at 72 °C and finally cooling at 4 °C. The PCR products (5 μL sample + 2 μL 6X 
loading dye) were run on a 1.2% agarose gel in 1X TBE to confirm the success of the 
amplification (specifics about gel electrophoresis are enumerated in the Agarose Gel 
Electrophoresis section of Materials and Methods). The remaining 45 μL were purified 
using QIAquick Nucleotide Removal Kit as follows: First, 10 volumes of Buffer PN1 
(add 19 mL of 100% isopropanol prior to use) were added to 1 volume of the reaction 
samples and mixed. The mixtures were applied to QIAquick columns and centrifuged for 
1 minute at 6000 rpm at room temperature (RT). The flow-through was discarded and the 
QIAquick columns were washed using 750 μL of Buffer PE (add 24 mL of 100% ethanol 
prior to use)  for 1 min. at 6000 rpm at RT. The DNA was eluted using 50 μL of 
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nuclease-free H2O by centrifugation for 1 minute.  Purified samples were stored at -20 
°C. 
 
Restriction Digestion 
Restriction digestion was performed on the 3’ BAC PCR product, 5’ BAC PCR product, 
and the pBluescript II KS(-) plasmid. The digestion solutions for the PCR products 
contained 45 μL of the purified 3’/5’ PCR product, 5 μL NEB 2.1 Buffer, 1 μL HindIII 
restriction enzyme (10 ng/μL), and 1 μL XhoI restriction enzyme (10 ng/μL). The 
pBluescript digestion solution contained 1 μL pBluescript plasmid (1 μg/μL), 2 μL NEB 
2.1 Buffer, 1 μL HindIII, 1 μL XhoI, and 15 μL nuclease-free H2O. Digested the three 
solutions at 37 °C for 3 hours, followed by purification using QIAquick Nucleotide 
Removal Kit (same protocol as explained in the PCR section of Materials and Methods). 
The samples (5 μL sample + 2 μL 6X loading dye) were then run on 1.2% agarose gel in 
1X TBE buffer (specifics about gel electrophoresis are enumerated in the Agarose Gel 
Electrophoresis section of Materials and Methods). The digested and purified 5’ probe, 3’ 
probe, and pBluescript were located using a 1 kB DNA marker, and the fragments were 
cut out using a razor with the gel under a U.V. light (cutting out as little agarose as 
possible). The nucleotides were purified using the Zymo Research Quick-gel DNA kit as 
follows: 3 volumes of agarose dissolving buffer (ADB) were added to each vial of 
recovered DNA-containing gel and incubated at 37 °C for 10 minutes. The dissolved 
solutions were loaded into Zymo-Spin Columns that filter into 1.7 mL collection tubes 
and centrifuged for 30 seconds. DNA was washed twice by adding 200 μL of DNA Wash 
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Buffer and centrifuged at full speed for 30 seconds. DNA eluted in 50 μL of nuclease-
free H2O. Samples were stored at -20 °C.  
 
 
Ligation  
Digested and purified pBluescript was dephosphorylated by adding 40 μL of the digested 
plasmid, 4 μL dephosphorylation buffer, and 4 μL of alkaline phosphatase and incubating 
at 37 °C for 30 minutes.  QIAquick Nucleotide Removal Kit was used to purify the 
dephosphorylated pBluescript (same protocol as explained in the PCR section of 
Materials and Methods). Two separate ligation mixtures were created – one for each of 
the probes. Both the 5’ and 3’ solutions contained a 1:10 ratio of pBluescript plasmid to 
digested probe. To each ligation solution, 100 ng of pBluescript (digested, 
dephosphorylated, and purified), 1000 ng of 3’/5’ probe (digested and purified), 2 μL of 
Ligation Buffer, and 1 μL of T4 DNA ligase were added. Nuclease-free H2O was added 
to each solution to bring the total volume to 20 μL. The two ligation mixtures were 
incubated at 16 °C overnight and stored at -20 °C.  
 
Transformation  
Four separate transformation mixtures were created – one positive control, one negative 
control, one mixture for 3’ probe + plasmid ligated product, and one mixture for 5’ probe 
+ plasmid ligated product. The positive control mixture contained 50 μL of competent 
DH5α cells and 1 μL of pure pBluescript (10 ng/μL). The negative control contained 50 
μL of competent DH5α cells and 1 μL of nuclease-free H2O, and each of the 3’/5’ probe 
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mixtures contained 50 μL of competent DH5α cells and 5 μL of the probe + plasmid 
ligated products (10 ng/μL). The tubes were placed first on ice for 3 hours and then in a 
42 °C water bath for 60 seconds, and then quickly transferred back to ice for 5 minutes. 
800 μL of S.O.C. medium (without ampicillin) was added to each vial, and the mixtures 
were shaken in a 37 °C incubator for 1 hour. After the samples settled down, 600 μL of 
solution was removed from the top. 10 μL of ampicillin (50 μg/μL) was added to each 
vial. For each of the four transformation mixtures, three 25 mL plates were made, each 
containing 25 mL of LB Agar (32 mg/mL) and 2 μL ampicillin (50 μg/μL). The 
transformation mixtures were plated using sterile spreaders in volumes of 100 μL, 50 μL, 
and 25 μL for each mixture on the LB Agar + ampicillin plates for a total of 12 plates. 
The plates were left at RT until the liquid was absorbed. Then, they were placed in the 
inverted position and incubated at 37 °C overnight. 3 colonies were selected from each 
plate and grown in LB Broth containing  ampicillin (from 100 mL stock solution of 20 
mg/mL LB Broth and 50 μg/mL ampicillin) by incubating (shaking) at 37 °C overnight. 
The negative control did not have any colonies. , DNA was isolated from a small aliquot 
of the culture using QIAGEN Plasmid Miniprep Kit as follows: After centrifugation, the 
supernatants were poured off and the pellets were resuspended in 250 μL Buffer P1. 250 
μL Buffer P2 was added and mixed followed by the addition of 350 μL Buffer N3 and 
subsequent mixing. The samples were centrifuged, the resulting supernatants removed, 
and applied to the QIAprep Spin Columns, leaving the white pellet in the discarded tubes. 
The columns were put over new 1.7 mL microcentrifuge tubes and centrifuged for 30-60 
seconds. The flow-through was discarded. The columns were washed with 0.75 Buffer 
PE and centrifuged for 30-60 seconds. The flow-through was discarded and the columns 
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were centrifuged again to fully remove the remaining wash buffer. The columns were put 
in fresh 1.7 mL centrifuge tubes, and the purified DNA was eluted with 50 μL nuclease-
free H2O and centrifugation. Isolated DNA samples were stored at -20 °C. 
 
Agarose Gel Electrophoresis  
In order to verify whether the probes were properly ligated into the pBluescript and 
transformed into the DH5α cells, the isolated DNA samples from the QIAprep Spin 
Miniprep Kit were run on an agarose gel. The DNA concentration of each sample was  
calculated by measuring the OD at 280 nm. For running the gel, two of the positive 
controls, seven 3’ probe DNA samples, and five 5’ probe DNA samples were selected 
based on DNA concentrations. The samples were then digested as explained in the 
Restriction Digestion section of Materials and Methods. These digestion mixtures, 
however, contained 1 μg of the purified 3’/5’/control DNA samples, 5 μL NEB 2.1 
Buffer, 1 μL HindIII restriction enzyme (10 ng/μL), and 1 μL XhoI restriction enzyme 
(10 ng/μL). The total volume of each solution was brought to 20 μL by adding the 
appropriate volume of nuclease-free H2O (depending on each individual sample 
concentration). After digestion, a 1.2% agarose gel in 1X TBE was loaded with 10 μL of 
the 1 kB DNA marker and 5 μL of the digested samples mixed with 2 μL of 6X loading 
dye. The gel ran for approximately 1 hour at 100V and was inspected under the U.V. 
light. DNA samples containing the 3’ and 5’ probes were identified using the DNA 
ladder. The two positive cultures that displayed the strongest fluorescent bands for each 
of the probes were then prepared to be used in QIAGEN Plasmid Maxi Kit to obtain 
larger quantities of the probe DNA necessary for nucleotide sequencing and in the 
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Southern Blot assay. To prepare for the Plasmid Maxi Kit, 100 μL of the chosen 3’ and 5’ 
probe were incubated in  200 mL of LB Broth (20 mg/mL) at 370C. The two cultures, one 
with DH5α cells containing the 3’ probe DNA ligated into pBluescript and the other with 
cells containing the 5’ probe DNA ligated into pBluescript, were used in the QIAGEN 
Plasmid Maxi Kit as follows: Both cultures were centrifuged at 6000g at 4 °C for 15 
minutes. The supernatants were discarded and the bacterial pellets were resuspended in 
10 mL Buffer P1 (RNase A must be added to the buffer prior to use). 10 mL Buffer P2 
was added, mixed, and incubated at RT for 5 minutes. 10 mL of pre-chilled Buffer P3 
was added, mixed, and incubated on ice for 20 minutes. Next, it was centrifuged at 
20,000g at 4 °C for 30 minutes, and the supernatants were isolated (discarding the 
pellets) and re-centrifuged under the same conditions for 15 minutes The supernatants 
were applied (in separate runs) to the QIAGEN-tip and allowed to enter the resin by 
gravity flow. For each run, the QIAGEN-tip was washed with 30 mL Buffer QC two 
times, allowing Buffer QC to move through the QIAGEN-tip by gravity flow. The DNA 
was eluted with 15 mL Buffer QF into two clean 50 mL containers. The DNA was 
precipitated by adding 10.5 mL of RT isopropanol to the eluted DNA solutions and 
mixed well. The solutions were then centrifuged for 30 minutes at 4 °C and the 
supernatants were decanted. The DNA pellets were washed with 5 mL of RT 70% 
ethanol and centrifuged for 10 minutes. The supernatants were decanted again. The 
pellets were air-dried for 5-10 minutes and the DNA was resuspended in 5 mL of 
nuclease-free H2O. 500 μL of sodium acetate was added to each sample and mixed. 10.5 
mL of cold 100% ethanol was added and placed on ice for 20 minutes. The mixtures were 
centrifuged for 15 minutes, and the supernatants were decanted. 1 mL of 70% ethanol 
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was mixed into the samples. Again they were centrifuged, and the supernatants were 
poured off. The purified DNA pellets were air-dried and resuspended in 1 mL of 
nuclease-free H2O. The DNA was stored at -20 °C.  
 
RESULTS 
Primer Construction 
 Sense and antisense primers were designed for the PCR amplification of the 5’ 
probe and the 3’ probe. Figures 1 and 2 show the association of the primers with the 
complimentary probe DNA strands for the 3’ probe and 5’ probes, respectively.
 
The lengths of the complimentary portion of the primers were chosen in order to 
maximize GC content. The lengths (not including the 5’ non-complimentary restriction 
sites) of the 3’-sense, 3’-antisense, 5’-sense, and 5’-antisense primers were determined to 
be 24 bp, 27 bp, 26 bp, and 26 bp for a total (including the 5’ restriction sites) of 33 bp, 
36 bp, 35 bp, and 35 bp, respectively. These primers have 73%, 60%, 51%, and 56% GC 
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content, respectively, which each fall above the recommended 50% threshold. For the 3’ 
probe, the melting temperatures (Tm)for the primers were 110 °C and 104 °C. For the 5’ 
probe, the melting temperatures (Tm) for the primers were 99 °C and 105 °C.  
 In order to introduce the XhoI and HindIII restriction sites flanking the probes, a 
sequence corresponding to the 6 bp restriction sites were put on the 5’ ends of the sense 
and antisense primers. 3 bp 5’ extensions were added to the ends of the non-
complimentary restriction sites because they have been shown to increase cleavage 
efficiencies of many restriction enzymes [12]. The most effective 5’ extension for the 5’-
CTGGAG-3’ XhoI cut site is 5’-CCG-3’, and the most effective 5’ extension for the 5’-
AAGCTT-3’ HindIII cut site is 5’-CCC-3’ [12]. So the 9 bp non-complimentary 
sequence chosen for both the 3’-sense and 5’-sense primers was 5’-CCGCTGGAG-3’, 
which introduced the XhoI restriction site. The 9 bp non-complimentary sequence chosen 
for both the 3’-antisense and 5’-antisense primers was 5’-CCCAAGCTT-3’, which 
introduced the HindIII restriction site. These aspects of the primers are shown in figures 1 
and 2, which show the complimentary portion of the primers annealed with the probe 
DNA strands and the 9 bp non-complimentary overhang to be integrated on either side of 
the probe DNA through PCR. 
 
PCR Amplification of Probes 
 The 5’ and 3’ probe PCR mixtures included PCR Platinum Supermix, the sense 
primer, the antisense primer, water, and varying volumes of DNA (BAC). Volumes of 2 
μL  (samples 2 and 6), 3.5 μL (samples 3 and 7), and 5 μL (samples 4 and 8) were used in 
the PCR mixtures. In order to determine whether the PCR was successful, the samples 
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were run on a 1.2% agarose gel with a 1 kB DNA marker and both 5’ and 3’ probe 
controls. Prior to running the gel, the replicated BACs are digested with XhoI and 
HindIII. The gel is shown in figure 3. 
 
 The successful PCR of the 5’ probe flanked with XhoI and HindIII restriction 
sites was confirmed by the alignment of the 5’ probe control (sample 1) with the 5’ probe 
PCR product that used 2 μL of DNA (sample 2). Samples 3 and 4 appeared to also 
contain some 5’ probe; however, the bands were smeared, indicating that these DNA 
samples were degraded at some point either during or after PCR. All 3 samples of 3’ 
probe PCR product (samples 6-8) showed crisp bands that aligned with the 3’ probe 
control, confirming the successful PCR of the 3’ probe flanked with XhoI and HindIII 
restriction sites. The distance the bands traveled with relation to the marker further 
authorized the presence of the probes. The 3’ probe is approximately 400 bp, so the 
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location of samples 5-8 slightly below the 500 bp marker band on the gel supported the 
notion that those bands were the 3’ probe. Furthermore, the 5’ probe is approximately 
350 bp, so the location of samples 1-4 slightly below both the 500 bp marker band and 
the 400 bp 3’ probe bands in samples 5-8 supported the identity of those bands as the 5’ 
probes.  
 
Probe Amplification by Molecular Cloning 
 In order to amplify the probes in large quantities to be in the Southern Blot assay, 
I further used molecular cloning technique. For this, the PCR products were digested, and 
the probes were ligated into a pBluescript II KS(-) plasmid that contained ampicillin 
resistance genes. The plasmids containing the probes were then transformed into 
competent DH5α cells and grown on agar plates containing ampicillin so as to select for 
colonies that took up the pBluescript during transformation. The molecularly cloned 
recombinant plasmids were then isolated and digested again. In order to initially verify 
whether the probes might have successfully inserted into the plasmid and transformed 
into the bacterial cells, gel electrophoresis on a 1.2% agarose gel was conducted and the 
results are displayed in figures 4 and 5. 
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Figure 4 shows the gel in its entirety and figure 5 is a more detailed and enlarged 
image of the bands in the verification gel electrophoresis. Samples control 1 (c1) and 
control 2 (c2) each showed one, albeit faint, band in their lanes. These bands had a 
relatively high molecular weight (MW) that corresponded to around 2800-3000 base 
pairs (bp) in length. This was most assuredly the linearized pBluescript sequence. 
Samples 1-12 showed two bands each. The band located towards at the top of the gel was 
the high MW pBluescript sequence, as it aligned at the same location as the control 
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pBluescript bands. The other, relatively lower MW band was clearly absent in both of the 
controls. These bands were our probes.  
There were two distinct versions of the small band. One group, in lanes 1-5, was a 
slightly smaller MW sequence than the sequence in lanes 6-12. The slightly smaller MW 
bands corresponded with the 5’ probe, and the bands in lanes 6-12 corresponded with the 
3’ probe. This is consistent with the fact that the 5’ probe is approximately 50 nucleotides 
shorter than the 3’ probe. Both the 3’ probe and 5’ probe bands fell in the range of the 
500 bp band in the marker. Since the 5’ probe is approximately 350 bp and the 3’ probe is 
about 400 bp, it likely that the identity of these sequences were our desired probes. 
Theoretically, these bands could have been any 350-400 nucleotide sequence; so, further 
sequencing is necessary to unquestionably confirm the presence of the probes in the 
plasmid. For sequencing (and the eventual use of the probe), greater quantities of the 
recombinant plasmids were required. The strongest band from the 5’ probe samples 
found in lane 2 and the strongest from the 3’ probe samples from lane 9 will be chosen to 
be sequenced and used as the probes in the Southern blot if the sequencing results came 
back positive. The cell cultures from which these recombinant DNA samples were 
harvested were used in the QIAGEN Plasmid Maxi Kit in order to obtain massive 
quantities of purified DNA. This DNA will then be sent to a nucleotide-sequencing lab 
for ultimate verification of the successful amplification of both probes. 
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Nucleotide Sequencing 
The purified and concentrated 5’ and 3’ probe DNA sequences were sent to a lab for 
nucleotide sequencing verification. The sequences of the 5’ and 3’ probes were 
confirmed: 
 
3’ Probe (5’ à 3’) 
CTCGAGGGGTGCACAGGGCTGGCAGGTTGGGACCCTTTCCTCCCCATGTGGA
TGCCGATGTGTTCCATGGTTTTACGAACATCTGCTCCACAGGCCTCTCACCCA
CCTGTTTGTTTGCCCGTGTGACAGAGCAAGGTGATGTCTCGGTACCCACCTTG
GAGCAACTGGAGAAGCTAAAGAAGATGGGGGACCTCCCCAGAGACCGTGCA
GGCAATGAAGGCATGGCTCTGCTTGCCTTTCTCTACCTGTACCTGGCAATCTG
CCGGAAGCAGAGGTGTGTGCATGGTCTATAGGAGCCCGTCCCTGGGAAGCAT
TCCGGAGAATCCCTGTGCCTCCACAGAGCAGGGAGTCCTGTAGTTTACAGTG
ATCCACTTGAGGTCTGGTGCCCATTTCCTGGTCGAAGCTT 
 
5’ Probe (5’ à 3’) 
CTCGAGTAGCAGCGCTACAACTTGTTTTGAACACTTGAACAGTGCACCTTTC
TTGTGGCTTCACACTTATGATGTATATTCAGACCCGTCACATGGCTACAGCGT
GGCCTACCTTTGTCTCCCGTCTTGGTGTAAATCTTGGGGATCTTGGCTGCCGT
CGAGGACGGCTGCAGCCTGATGAGAAACAGACACAAAGGCGTGGTAAGTGG
GAACGGCTGCGCCTCGGGGAGTGACGCCCAGCTTTCAGTCTGCAACCTCAGG
GGCAGCACTTCTCTGCCTCTGGGATGGCAATCTCCCGTCAGCCATTTCCAAGC
TT 
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DISCUSSION 
 In this section, the design of the targeting vector, the breeding scheme to be 
conducted by the TAMC, and how the amplified 3’ and 5’ probes play a role in MvK 
cKO mice formation will all be discussed. The first step conducted in the creation of the 
MvK cKO mice was the creation of a BAC containing the mutated Mevk1 targeting 
vector. The Cre-loxP approach was used as the targeting scheme to specifically delete 
Mevk1 in the granulosa cells. In the scheme shown in figure 6, through homologous 
recombination in ES cells, a loxP recombination site was introduced in intron 1 of Mevk1, 
and another loxP site and an FRT-flanked PGK-Neo cassette were introduced in intron 3 
of Mevk1, creating a “floxed” Mevk1 gene. 
 
Lox P sites contain 34 bp – a 13 bp palindromic sequence followed by 8 random 
bp and another 13 bp palindromic sequence [13]. The two loxP sites introduced into 
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Mevk1 were oppositely oriented and are recombined by Cre recombinase, deleting the 
sequence between the two recombination sites when Cre recombinase is expressed. Since 
the ATG start codon for Mevk1 is located in exon 2, the MvK cKO mice with deleted 
exon 2 are not able to form a functional MvK protein. The deletion of MvK throughout 
the entire body is fatal; so the expression of Cre recombinase must be limited to the 
mouse ovaries alone in this construct. This was achieved using the Cre genes controlled 
by a Cyp19 promoter. Cyp19-Cre+ mice show expression of Cre exclusively in the 
ovaries and have been successfully used in the past to create granulosa cell-specific 
knockout mice [14].  
 The PGK-Neo cassette was introduced into the targeting vector to be used in the 
selection of ES cells that successfully obtained the targeting vector through homologous 
recombination. The cassette is a drug-selection cassette that renders cells resistant to the 
drug neomycin. When introduced into the targeting vector, the cassette was flanked by 
FRT recombination sites, as shown in figure 6. FRT recombination sites are recombined 
by FlpO recombinase [15]. Deletion of the drug-selection cassette in the final MvK cKO 
mice is conducted by breeding with FlpO transgenic mice.  
  The use of the amplified 3’ and 5’ probes comes into play after the homologous 
recombination has occurred in the ES cells and selection on neomycin plates due to the 
presence of the PGK-Neo cassette has transpired. The stem cells that are neomycin-
resistant will be sent back to our lab for Southern blot analysis. The 5’ and 3’ probes are 
radioactively labeled for use in the assay. The sequences complimentary to the amplified 
5’ and 3’ probes flank the targeting vector; therefore, if the ES cell DNA binds both the 
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3’ and the 5’ probes as displayed in the Southern blot assay, then the ES cell contains the 
desired genetically engineered Mevk1 targeting vector.  
 
 Once the Southern blot analysis correctly identifies the ES cells containing the 
homologously recombined targeting vector, the results will be sent back to the TAMC, 
and the breeding scheme shown in figure 7 is conducted. The mutant ES cells carrying 
the floxed allele will be injected into blastocysts, which will be injected into pregnant 
female mice. Some of the progeny will be chimeric agouti mice carrying the floxed allele 
(F0 generation). Male chimeras will then be mated with FlpO transgenic females, 
excising the FRT-flanked PGK-Neo cassette in the F1 generation mice. The F1 MVKflox/+ 
mice will be subsequently mated with Cyp19-Cre+ female mice to obtain heterozygous 
MVKflox/+Cre+ F2 generation mice. The heterozygous F2 mice will finally be intercrossed 
until homozygous MVKflox/floxCre+ mice (MvK cKO mice) are produced that will have 
granulosa-specific deletion of LRBP/MvK.  
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 The creation and amplification of the probes for use in the development of a 
Southern blot verification assay and the design of the targeting vector are two of the first 
steps required in the creation of MvK cKO mice. These are two of the primary 
responsibilities of our lab in the creation of the transgenic mice. Moving forward, before 
the TAMC will carry out the steps to create the MvK cKO mice, our lab must produce a 
mock Southern blot assay using our amplified probes to show the TAMC, which will 
prove that we can properly conduct an assay that will identify the correct ES cells. This is 
the final step in the path towards the creation of the MvK cKO mice as far as Menon Lab 
is concerned. Once the MvK cKO mice are created, we will be able to observe the 
hypothesized wide-ranging effects on mice that are unable to express LRBP in the 
ovaries. The MvK cKO mice will allow us to examine how important LRBP is in LHR 
mRNA down-regulation, and how the absence of LRBP affects key players in the post-
LH surge LHR down-regulation.  
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